Eli Lilly (LLY), which is suffering from a massive patent cliff and faces another one in 2017,...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly (LLY), which is suffering from a massive patent cliff and faces another one in 2017, could keep marketing exclusivity for its blockbuster Alimta lung cancer drug until 2022 rather than 2016 if it wins a case over a "method-of-use" patent on the way the multibillion dollar selling treatment is administered. Such IP is usually not upheld, although some experts believe that the Alimta case is different. Generic firms such as Teva (TEVA) argue otherwise.